ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
33 hedge funds and large institutions have $297M invested in ESSA Pharma in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 4 closing their positions.
78% more call options, than puts
Call options by funds: $492K | Put options by funds: $277K
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
30% more capital invested
Capital invested by funds: $229M → $297M (+$68M)
6% more funds holding
Funds holding: 31 → 33 (+2)
0.42% more ownership
Funds ownership: 78.78% → 79.2% (+0.42%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$4.85M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.88M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$3.22M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$2.2M |
| 5 |
Janus Henderson Group
London,
|
+$749K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$6.44M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.46M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.98M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.17M |
| 5 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$269K |
EPIX Hedge Fund Activity: Q1 2024 in Review
33 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q1 2024, worth a combined $297M — up 30% from $229M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new EPIX positions and 4 closed out — a net gain of 2 holders — while 5 added to existing stakes and 10 trimmed.
The largest buyer was Rhenman & Partners Asset Management, adding an estimated $4.85M. The largest seller was Soleus Capital Management, cutting an estimated $6.44M.
- 33 institutional investors held ESSA Pharma (EPIX) as of Q1 2024, up from 31 in Q4 2023.
- Funds reported $297M of ESSA Pharma stock for Q1 2024, up 30% quarter-over-quarter.
- 6 funds opened new ESSA Pharma positions in Q1 2024 and 4 closed out, a net change of +2 holders.
- The largest ESSA Pharma buyer in Q1 2024 was Rhenman & Partners Asset Management, an estimated $4.85M added.
- The largest ESSA Pharma seller in Q1 2024 was Soleus Capital Management, an estimated $6.44M sold.
Based on aggregated 13F filings for Q1 2024.